PE20020434A1 - Metodo de tratamiento de la enfermedad de parkinson - Google Patents

Metodo de tratamiento de la enfermedad de parkinson

Info

Publication number
PE20020434A1
PE20020434A1 PE2001001012A PE2001001012A PE20020434A1 PE 20020434 A1 PE20020434 A1 PE 20020434A1 PE 2001001012 A PE2001001012 A PE 2001001012A PE 2001001012 A PE2001001012 A PE 2001001012A PE 20020434 A1 PE20020434 A1 PE 20020434A1
Authority
PE
Peru
Prior art keywords
cycloalkyl
alkyl
parkinson
disease
treatment
Prior art date
Application number
PE2001001012A
Other languages
English (en)
Inventor
Kjell A Svensson
Original Assignee
Upjohn Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Upjohn Co filed Critical Upjohn Co
Publication of PE20020434A1 publication Critical patent/PE20020434A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

SE REFIERE A UN METODO PARA EL TRATAMIENTO DE LA ENFERMEDAD DE PARKINSON QUE COMPRENDE ADMINISTRAR EN FORMA CONCOMITANTE: a) DE 1mg A 2000 mg DEL COMPUESTO DE FORMULA I O FENILAZACICLOALCANO SUSTITUIDO DONDE n ES 1-2; R1 Y R2 SON INDEPENDIENTEMENTE H, SIEMPRE QUE AMBOS NO SEAN H, OH, CH, CH2CN, 2- O 4-CF3, CH2,CF3, CH2CHF2, CH=CF2, ETENILO, ENTRE OTROS; R3 ES H, CF3, CH2CF3, ALQUILO C1-C8, CICLOALQUILO C3-C8, CICLOALQUIL-METILO C4-C9, ALQUENILO C2-C8, ENTRE OTROS; R4 Y R SON H, CF3, CH2CF3, ALQUILO C1-C8, CICLOALQUILO C3-C8, ENTRE OTROS. UN COMPUESTO PREFERIDO ES (S)-(-)-3-METILSULFONILFENIL-1-PROPILPIPERIDINA; b) UN AGONISTA DE DOPAMINA L-DOPA SELECCIONADO DE APOMORFINA, BROMOCRIPTINA, PERGOLIDA, ROPINIROL, PRAMIPEXOL
PE2001001012A 2000-10-12 2001-10-12 Metodo de tratamiento de la enfermedad de parkinson PE20020434A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US23982800P 2000-10-12 2000-10-12

Publications (1)

Publication Number Publication Date
PE20020434A1 true PE20020434A1 (es) 2002-06-17

Family

ID=22903911

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2001001012A PE20020434A1 (es) 2000-10-12 2001-10-12 Metodo de tratamiento de la enfermedad de parkinson

Country Status (7)

Country Link
US (1) US6653325B2 (es)
EP (1) EP1404326A4 (es)
JP (1) JP2004528283A (es)
AU (1) AU2002246490A1 (es)
CA (1) CA2425125A1 (es)
PE (1) PE20020434A1 (es)
WO (1) WO2002056745A2 (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE46117E1 (en) 1999-12-22 2016-08-23 Teva Pharmaceuticals International Gmbh Modulators of dopamine neurotransmission
EP2561860B1 (en) * 2002-05-31 2018-02-28 Titan Pharmaceuticals, Inc. Implantable polymeric device for sustained release of buprenorphine
MXPA05010450A (es) * 2003-03-31 2005-11-04 Titan Pharmaceuticals Inc Dispositivo polimerico implantable para la liberacion prolongada de agonistas de dopamina.
US20060105036A1 (en) 2003-05-12 2006-05-18 Stephen Peroutka Threo-dops controlled release formulation
US8158149B2 (en) * 2004-05-12 2012-04-17 Chelsea Therapeutics, Inc. Threo-DOPS controlled release formulation
WO2005025561A1 (en) * 2003-09-04 2005-03-24 Synergia Pharma, Inc. Compositions and methods for orthostatic intolerance
US20080038198A1 (en) * 2004-01-05 2008-02-14 Mitsubishi Pharma Corporation Method Of Screening Molecule Associated With Psychiatric Disorder
ES2383768T3 (es) * 2006-06-28 2012-06-26 Chelsea Therapeutics Inc. Composiciones farmacéuticas que comprenden droxidopa
TW200815045A (en) * 2006-06-29 2008-04-01 Jazz Pharmaceuticals Inc Pharmaceutical compositions of ropinirole and methods of use thereof
JP2010520885A (ja) * 2007-03-09 2010-06-17 チェルシー・セラピューティクス，インコーポレイテッド 線維筋痛症の治療のためのドロキシドパ及びその医薬組成物
US8383681B2 (en) * 2007-05-07 2013-02-26 Chelsea Therapeutics, Inc. Droxidopa and pharmaceutical composition thereof for the treatment of mood disorders, sleep disorders or attention deficit disorders
ES2528040T3 (es) * 2007-06-18 2015-02-03 A.Carlsson Research Ab Uso de estabilizadores de dopamina
JP5880913B2 (ja) 2011-05-17 2016-03-09 三郎 佐古田 パーキンソン病の体幹症状（姿勢反射異常）の治療剤
WO2013086304A1 (en) * 2011-12-07 2013-06-13 Board Of Regents Of The University Of Nebraska Methods and compositions for diagnosing neurodegenerative disease
WO2014172372A1 (en) 2013-04-15 2014-10-23 Northwestern University Treatment for dopaminergic disorders
WO2015061777A2 (en) * 2013-10-25 2015-04-30 Oral Alpan Therapy for chronic idiopathic urticaria, anaphylaxis and angioedema

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3176063B2 (ja) * 1991-04-17 2001-06-11 ファルマシア・アンド・アップジョン・カンパニー 新規中枢神経作用性置換フェニルアザシクロアルカン類
SE9702716D0 (sv) * 1997-07-15 1997-07-15 Ross Nicholas Waters Substituted phenylazacycloalkanes in the treatment of cognitive disorders
SE9802546D0 (sv) * 1998-07-15 1998-07-15 Ross Nicholas Waters Medicinal product and method for treatment and prevention of dyskinesia

Also Published As

Publication number Publication date
WO2002056745A2 (en) 2002-07-25
EP1404326A4 (en) 2004-06-30
CA2425125A1 (en) 2002-07-25
AU2002246490A1 (en) 2002-07-30
JP2004528283A (ja) 2004-09-16
US20020049232A1 (en) 2002-04-25
WO2002056745A3 (en) 2004-01-08
US6653325B2 (en) 2003-11-25
EP1404326A2 (en) 2004-04-07

Similar Documents

Publication Publication Date Title
PE20020434A1 (es) Metodo de tratamiento de la enfermedad de parkinson
PE46597A1 (es) Agonista de estrogeno
ES2313079T3 (es) Benzimidazol, benzotiazol, benzoxazol y su utilizacion como moduladores de lta4h.
UY26974A1 (es) Agonistas del receptor beta3 adrenérgico y usos de los mismos
PE20060988A1 (es) Sintesis asimetrica de dihidrobenzofuranos sustituidos
GB0517191D0 (en) Compounds
CY1107956T1 (el) Χρηση υποκατεστημενων 2-αμινοτετραλινιων για την προληπτικη αντιμετωπιση της νοσου του παρκινσον
PE11698A1 (es) Compuestos de 6-dimetilaminometil-1-fenil ciclohexano y procedimiento para el uso de dichos compuestos
PE59999A1 (es) Derivados de 1,3,8-triaza-espiro[4,5]decan-4-ona-8-sustituidos
PE20001084A1 (es) Agentes farmaceuticos para el tratamiento de la enfermedad de parkinson, adhd y microadenomas
CO5700726A2 (es) Compuestos organicos
CR20110376A (es) Proceso para preparar clorhidrato de oxicodona teniendo menos de un 25 ppm 14-hydroxycodeina (divisional exp. 8593)
BR0215898A (pt) Composição e método para a formação não permanente durável de pelo menos uma fibra queratìnica ou para a retenção durável de uma forma não permanente de pelo menos uma fibra queratìnica e kit para proteger pelo menos uma fibra queratìnica contra danos extrìnsecos
UY28280A1 (es) 2- hidroxi - 3- diaminoalcanos de benzamida
CN1942179A (zh) 用于治疗不安腿综合征和成瘾症的α－氨基酰胺衍生物
AR082343A2 (es) Un metodo de reduccion de desgaste por rozamiento para combustibles y procedimiento para preparar una composicion combustible
PE20020917A1 (es) Derivados de imidazol como bloqueadores del receptor n-metil-d-aspartato
WO2007002945A3 (en) P2y6 receptor agonists for treating lung diseases
PE20050484A1 (es) Composicion farmaceutica de liberacion sostenida
PE20050420A1 (es) Fenacilo 2-hidroxi-3-diaminoalcanos
RU2008142261A (ru) Фармацевтическая композиция с модифицированным высвобождением и ее применение
PE20061083A1 (es) Composicion farmaceutica que comprende benzoxazoles sustituidos
UA105649C2 (uk) Хінолонова сполука і фармацевтична композиція
BRPI0416564A (pt) novas prostamidas para o tratamento de glaucoma e doenças relacionadas
AR036351A1 (es) Isoxazolopiridinonas, el uso de las mismas para la fabricacion de un medicamento, composiciones y combinaciones farmaceuticas

Legal Events

Date Code Title Description
FC Refusal